Board summary
Key figures
45,518
Registered population
55.6% aged 18–64
27.6%
Aged 65+
ICB 19.9% · England 17.9%
6.7%
Ethnic minority (non-White)
2.5% Asian · England 9.6%
10.0%
In IMD quintile 1
ICB 17.1% · England 21.0%
~3,586
Core20 residents (est.)
Resident basis; registered basis ~4,552 · see page 3
7,918
Hypertension register
+2.83% in 3 yrs · England +5.60%
422
SMI register
20% of Canterbury's
1,143
COPD register
Reviews -4.32% in 3 yrs
Forecast to 2030
9,240
Hypertension patients, 2030
+1,322 on today
71.6%
QRISK ≥20% on statins, 2030
+5.20pp over 3 yrs
7.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Heart failure reviews fell below England.
Heart failure reviews stand at 66.0% versus 78.5% in England after falling 10.2% over three years (England +8.7%), which may reflect recall pressure.
Asthma reviews and youth smoking checks lag.
Asthma reviews reached 57.1% (England 65.7%), leaving about 1,400 of 3,343 register patients unreviewed, alongside 61.8% youth second-hand smoke recording (England 78.8%).
Breast and cervical screening exceed national rates.
Breast screening reached 80.7% (England 69.9%) after a +13.4% 3-year change (England +8.4%), while cervical screening in ages 25-49 reached 77.3% (England 66.8%).
Population, age and ethnicity
Older age profile dominates with 27.6% aged 65+ against 17.9% across England
Whitstable PCN comprises 45,518 registered patients. Among registered patients, 27.6% (12,583 patients) are aged 65+, exceeding Canterbury (18.4%), NHS Kent and Medway ICB (19.9%), and England (17.9%), while ages 18–64 represent 55.6% and ages 0–17 represent 16.8%. Area Census data shows 93.3% identifying as White (Canterbury 89.2%, ICB 88.6%, England 81.1%) and 2.5% as Asian / Asian British (Canterbury 4.0%, ICB 4.7%, England 9.6%). Projected population growth to 2030 is 6.3% (Canterbury 7.0%, ICB 6.0%, England 2.3%), using unverified forecast methodology.
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Canterbury local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Canterbury LA) | 1,577 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.2% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 57.9% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Canterbury LA) | 682 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Canterbury LA) | 18.2 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 share is 10.0% versus 21.0% in England, covering six decile two LSOAs
Whitstable PCN has an average IMD decile of 6.8, reflecting lower deprivation than Canterbury (5.7), NHS Kent and Medway ICB (5.4), and England (5.5). Its Core20 share is 10.0% (Canterbury 19.3%, ICB 17.1%, England 21.0%). However, Core20 headcounts diverge between bases: 3,586 associated residents live in 6 national decile 2 LSOAs, whereas applying the 10.0% registered share to the single practice (Whitstable Medical Practice, list 45,518) produces 4,552 patients. The PCN should reconcile resident LSOA mapping against practice postcode registers before committing outreach resources.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
422
SMI register
0.95% recorded prevalence
231
Learning disability register
0.52% recorded prevalence
31
Care homes, 1,120 beds
In the PCN catchment
9.3%
Provide unpaid care
Canterbury, Census 2021
The PCN records 231 learning disability patients (0.5% vs 0.6% in Canterbury, NHS Kent and Medway ICB, and England) and 422 severe mental illness patients (0.9% vs Canterbury 1.1%, ICB 0.9%, England 1.0%). Catchment services include 31 care homes with 1,120 beds, though bed capacity does not establish registered patient occupancy.
Severe mental illness: physical health checks
Among 422 severe mental illness patients, blood pressure checks reached 84.6% (England 83.4%), while BMI recording was 80.8% (England 82.1%) and alcohol recording was 71.9% (England 81.8%). Separate check elements show uneven physical health monitoring across the cohort.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,918
Hypertension register
+2.83%
Register growth, 3 yrs
Canterbury +3.48% · England +5.60%
−0.27pp
BP control, under 80
≤140/90 · −3.98pp aged 80+
+1,322
More patients by 2030
Forecast 9,240 (18.76%)
Hypertension case-finding and control
Hypertension recorded prevalence is 17.7% (7,918 patients), above England (15.2%), Canterbury (15.6%) and NHS Kent and Medway ICB (16.2%), although crude prevalence is not age-adjusted. Register growth was +2.8% over three years (England +5.6%). Blood pressure recording reached 86.2%, trailing England (90.0%) and the ICB (87.3%), falling 0.8% over three years while England rose +3.6%. Furthermore, blood pressure control in patients aged 80 and over stands at 75.4%, below England (81.2%), Canterbury (78.3%) and the ICB (78.3%), after falling 5.0% over three years (England +2.2%). Lower recording and control rates than England could reflect monitoring gaps in older cohorts, which structured reviews could test.
Lipids and statins
For patients with QRISK ≥ 20%, lipid-lowering therapy uptake is 59.6%, trailing England (63.6%) despite growing +9.6% over three years (England +6.2%). CKD treatment reaches 72.3% (England 70.3%). Lower uptake than England could reflect primary prevention review timing.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 75,301 | £2.40 | £1.90 | £1.86 | £180,722 |
| Cardiovascular (all), 2025 | 102,229 | £4.04 | £3.57 | £3.33 | £413,005 |
In 2026, lipid-regulating drug prescribing totaled 75,301 items at £2.40 per item (£180,722 spend), above Canterbury (£2.23), NHS Kent and Medway ICB (£1.90) and England (£1.86), spending £40,663 more than at England's unit cost. Higher unit spend may reflect formulary choices rather than inefficiency.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+7.48%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+5.98%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.8% (3,343 patients; England 6.6%) and COPD prevalence is 2.6% (1,143 patients; England 1.9%). Annual reviews trail England for asthma at 57.1% (England 65.7%, leaving about 1,400 unreviewed) and COPD at 69.1% (England 76.4%), where reviews fell 4.3% over three years (England +2.8%). Second-hand smoke recording for ages 6–19 is 61.8% (England 78.8%), alongside 1,689 asthma items prescribed per 1,000 youth (England 1,488). Lower review rates than England could reflect review capacity across respiratory clinics.
Cancer register and children's immunisation
Cancer prevalence is 6.5% (2,895 patients; England 3.8%). In childhood immunisations for Q1 2025/26, MMR dose 1 coverage reaches 97.0% by age 5 (England 91.7%), but MMR dose 2 is 7.4 pp lower at 89.6% (England 82.8%), standing 5.4 pp below the 95.0% target in cohort denominator 67. The drop between doses suggests attrition before primary school entry.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
Across NHS Kent and Medway ICB in 2022, 55.6% of cancers with a known stage were diagnosed at stage 1 or 2 (4,661 of 8,384), in line with England (55.3%) but 19.4 pp below the 75.0% national ambition. Known stage was recorded for 63.6% of registered cancers (8,384 of 13,189; England 67.0%). Reaching the 75.0% ambition would require 1,627 additional early-stage diagnoses yearly across the ICB. These figures describe ICB-level delivery, not PCN performance. At Whitstable PCN, 2,895 patients are on the cancer register (6.5%), with three-year register growth of +7.8% (England +9.0%).
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), East Kent Hospitals University NHS Foundation Trust achieved 70.0% on the 62-day cancer referral to treatment standard (15.0 pp below the 85.0% standard; NHS Kent and Medway Integrated Care Board 75.9%, England 71.2%) and 71.3% on the 28-day faster diagnosis standard (standard 75.0%). For diagnostics in July 2026, 48.4% of patients waited 6+ weeks at East Kent Hospitals (Medway NHS Foundation Trust 14.2%, England 23.1%), including non-obstetric ultrasound (63.0%), MRI (47.6%), and colonoscopy (9.6%). These provider figures describe secondary care activity, not PCN performance.
| Pathways within standard (%) | East Kent | Mid and South Essex | Medway | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 71.28 | 67.45 | 77.77 | 76.78 | 79.32 |
| 31-day treatment (96%) | 96.67 | 81.88 | 99.62 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 70.01 | 50.25 | 81.64 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Kent | Mid and South Essex | Medway | England |
|---|---|---|---|---|
| MRI | 47.58 | 23.35 | 0.68 | 21.40 |
| CT | 37.45 | 6.07 | 0.00 | 9.92 |
| Echocardiography | 14.17 | 65.05 | 36.62 | 28.48 |
| Colonoscopy | 9.58 | 64.09 | 1.88 | 30.83 |
| Gastroscopy | 22.16 | 59.76 | 3.32 | 29.02 |
| All 15 DM01 tests | 48.38 | 41.54 | 14.20 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). In June 2026 (provisional), Kent residents accounted for 210,170 community care contacts and 60,605 individual patients, within 254,055 contacts across NHS Kent and Medway Integrated Care Board. Adults aged 65+ represented 65.8% of Kent contacts (138,250). New community referrals reached 59,360 in Kent (ICB 68,085). These community statistics describe local authority and ICB activity, not PCN performance.
Practice variation and patient experience
Overall QOF achievement reached 97.1% and patient experience 86.4%, both exceeding England
In 2025/26, Whitstable Medical Practice achieved 97.1% overall QOF points (England 92.5%) and 100.0% in the clinical domain (England 97.1%). Personalised care adjustments were 9.2% overall (England 10.0%) and 3.8% in vaccination and immunisation (England 4.2%), where points reached 74.7% (England 55.2%). Recorded achievement exceeds England across overall, clinical, and vaccination domains.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Whitstable | 186 | 10.0 | 70.2% | 77.4% | 86.4% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Twelve of 25 compared measures trailed England's three-year trends despite screening gains
Across 25 compared measures, 12 trailed England's three-year change. Relative reviews fell for heart failure by 10.2% (England +8.7%), leaving current coverage at 66.0% (England 78.5%), and COPD fell 4.3% (England +2.8%). Blood pressure control in patients aged 80+ fell 5.0% to 75.4% (England +2.2% to 81.2%), while smoking cessation offers dropped 3.0 pp (England +0.1 pp). Conversely, three-year gains exceeded England in breast screening (+13.4% vs +8.4%) and asthma reviews (+7.5% vs +4.4%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
BP control, 80+
COPD reviews
Hypertension BP reading
Hypertension treated to target
Breast screening (53-70)
QRISK statin treatment
Asthma reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Canterbury | Asset | PCN | Canterbury |
|---|---|---|---|---|---|
| Care homes (catchment) | 31 (1,120 beds) | n/a | Schools (catchment) | 45 | n/a |
| Children's centres | 4 | 8 | Places of worship | 57 | 103 |
| Libraries | 2 | 2 | Day centres (VCS) | 1 | 4 |
| Children and young people (VCS) | 1 | 1 | Carers support groups (VCS) | 1 | 4 |
| Primary schools (LA maintained) | 12 | 19 | Primary academies | 5 | 13 |
| Special schools | 1 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma and youth smoking recall
Annual asthma reviews reached 57.1% of 3,343 patients versus 65.7% in England (8.6 pp below; about 1,400 unreviewed), with youth smoke recording at 61.8% (England 78.8%). For discussion: Whitstable Medical Practice could run structured recall using a review template prompting second-hand smoke recording for ages 6-19 and offering after-school slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Pre-school MMR2 and booster recall
In Q1 2025/26 (cohort 67), age-5 coverage fell 7.4 pp from MMR1 (97.0%) to MMR2 (89.6%), leaving MMR2 and 4-in-1 (89.6%) 5.4 pp below the 95.0% target. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
Learning disability register validation
Recorded learning disability prevalence is 0.5% (231 of 45,518 patients) versus 0.6% in Canterbury, the ICB, and England, giving a modelled gap of +32 to +37 patients. For discussion: Whitstable Medical Practice could cross-check clinical records for unlinked diagnostic codes and review transition records with social care where sharing exists. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Core20 list reconciliation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health check recall (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Older hypertension blood pressure review (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cancer safety-netting review (p7) | Cancer: QOF prevalence | Core20PLUS5, 75% stage 1–2 by 2028 | PCN |
| Option 1 · Structured asthma and youth smoking recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Pre-school MMR2 and booster recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 3 · Learning disability register validation (p12) | Learning disability register · Learning disability: QOF prevalence · Registered population | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
